SHorter Treatment of Replacement Therapy for Frozen Embryo Transfer (FET)

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Infertility
Interventions
OTHER

Longer administration of estradiol (Progynova®)

All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).

Trial Locations (1)

1090

Universitair Ziekenhuis Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER

NCT03930706 - SHorter Treatment of Replacement Therapy for Frozen Embryo Transfer (FET) | Biotech Hunter | Biotech Hunter